Cu(II) binding to the ␣ prion protein (␣PrP) can be both intramolecular and intermolecular. X-ray absorption spectroscopy at the copper K-edge has been used to explore the site geometry under each binding mode using both insoluble polymeric Cu(II)⅐␣BoPrP-(24 -242) (bovine PrP) complexes and soluble Cu(II) complexes of peptides containing one, two, and four copies of the octarepeat. Analysis of the extended region of the spectra using a multiple scattering approach revealed two types of sites differing in the number of His residues in the first coordination shell of Cu(II). Peptides containing one and two-octarepeat copies in sub-stoichiometric Cu(II) complexes showed the direct binding of a single His in accord with crystallographic intra-repeat geometry. Alternatively, the polymeric Cu(II)⅐␣BoPrP-(24 -242) complex and Cu(II) in its soluble complex with a fouroctarepeat peptide at half-site-occupancy showed Cu(II) directly bound to two His residues, consistent with an inter-repeat binding mode. Increasing the Cu(II) site occupancy from 0.5 to 0.75 in the peptide containing four octarepeats resulted in spectral features that are intermediate to those of the inter-and intra-repeat modes. The transition from His-Cu-His (inter-repeat) to Cu-His (intra-repeat) on increasing Cu(II) saturation offers a structural basis for the positive cooperativity of the cation binding process and explains the capacity of ␣PrP to participate in Cu(II)-mediated intermolecular interactions.PrP C , 1 a two-domain protein, has become a key molecule for understanding the group of lethal neurodegenerative disorders known as prion diseases (1). These disorders are characterized by the over-stabilization of alternative conformers (PrP Sc ) of the cellular prion protein with acquired self-perpetuating properties (1-3). Even though the structural changes occur at the C-terminal domain, the N-terminal region plays a regulatory role in the overall process leading to the conversion of PrP C into PrP Sc (4 -7). Among the different functions attributed to PrP C , Cu(II) interaction is, to date, the only one that has been correlated with physiological impairments linked to the disease (8).Cu(II) interaction was first described in the protocol tailored for PrP C purification and attributed to the His residues of the N-terminal domain (9 -19). These residues are located within the tandemly repeated PHGGGWGQ sequence known as the octarepeat and at the flexible hinge that connects the N-terminal and C-terminal domains (16 -20). In addition to these, other minor Cu(II)-binding sites in the C-terminal globular domain have been reported (19,21,22). Studies with PrP C models, as synthetic peptides and recombinant forms, have shown binding stoichiometries of up to one Cu(II) per octarepeat motive in a process in which the interaction among cation sites, measured as positive cooperativity, appears when the number of sites is higher than two (15,18,(22)(23)(24). The binding affinity constants varied in the femto to micromolar range and show strong pH dependenc...